UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

UltraSight (formerly OnSight Medical), a Digital Health pioneer for cardiac imaging and beyond, announced today that it has closed a $13 million Series B funding round.

The investment will be used to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings. The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

UltraSight’s AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping more patients be accurately diagnosed and treated.  Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonography is a skill that takes years to acquire and requires daily practice to maintain high proficiency, creating a shortage in these highly specialized professionals. UltraSight aims to change this dynamic by offering clinicians with no prior sonography training, automated guidance and quality assessment, for conducting ultrasound scans.

UltraSight also announced the strengthening of its medical and scientific advisory board with the appointment of Al Lojewski, former General Manager Cardiology Solutions at GE Healthcare, Laurance Grossman, MD, Radiologist at Cleveland Clinic, and Andrew Cleeland, CEO of Fogarty Innovation.

“We see a future where ultrasound is readily available to assess any patient, anywhere and by any healthcare professional. Simplifying ultrasound is critical to providing fast, effective care,” said Andrew Cleeland, CEO of Fogarty Innovation. “By making ultrasound ubiquitous, UltraSight has the potential to bring the benefits of cardiac imaging to more healthcare professionals and new care settings.”

“UltraSight provides a novel and versatile platform that addresses the unmet needs of patients and physicians,” said Davidi Vortman, CEO of UltraSight. “This financing round places us on the path to become a leading player in the ultrasound industry.”

“We are excited to help realize UltraSight’s mission,” said Wonjae Lee, Head of Asia Pacific, The Yozma Group. “UltraSight’s innovation is poised to reshape the ultrasound market and propel market growth.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version